Bill117th CongressFiled May 3, 2022Health
H.R. 7640
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it doesSummary introduced in house (May 3, 2022)
This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.
What just happenedMay 3, 2022
Referred to the House Committee on Energy and Commerce.
Who’s behind it
Rep. Bilirakis, Gus M. [R-FL-12](R-FL)Sponsor
1 cosponsor1 D
1cosponsors1committees3actions1related bills
- Introduced in HouseMay 3, 2022
- May 3, 2022IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - May 3, 2022IntroReferralIntro-H
Introduced in House
- May 3, 2022IntroReferral1000
Introduced in House